06 September 2018 | News
Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health
Mundipharma has closed an asset purchase agreement with Vital Food Processors Limited, an agricultural science company founded in New Zealand, for the global rights beyond New Zealand to commercialise Zyactinase™, a clinically-proven gastrointestinal consumer health product.
Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulate increased bowel movements.
Under the agreement, Mundipharma will initially focus on the commercialising Zyactinase™ to establish a foothold in the US and Canada markets, while continuing to supply existing partners. It will then look to expand its marketing and distribution footprint globally.
This agreement will also enable the extension of the company's Senokot® product range in the US, which is also an all-natural, clinically proven digestive health supplement for the treatment of constipation.
"We are delighted to have realised this opportunity to acquire a unique, clinically-proven differentiated formulation for commercialisation on a global basis across our network," said Mundipharma CEO, Raman Singh.